Skip to main content
. 2018 May 9;20(Suppl E):E12–E15. doi: 10.1093/eurheartj/suy016

Table 1.

Pharmacokinetic and pharmacodynamic properties of direct oral anticoagulants18,19

Betrixaban Apixaban Edoxaban Rivaroxaban Dabigatran
Target Factor Xa Factor Xa Factor Xa Factor Xa Thrombin
Half-life (h) 19–27 12 10–14 5–9 12–17
Dosing o.d. b.i.d. o.d. o.d. (b.i.d.) b.i.d.
Tmax (h) 3–4 1–3 1–2 2–4 2
Bioavailability (%) 34 50 62 66 7
Renal excretion (%) 17.8a 25 35 66 >80
Faecal excretion (%) 85b 46.7–56 62.2 26.4 82–88
CYP450 metabolism No Yes No Yes No

b.i.d., twice daily; o.d., once daily; Tmax: time to reach peak concentration in plasma after oral dose.

a

Unchanged betrixaban in urine following an intravenous betrixaban dose.

b

Following oral administration of radio-labelled betrixaban.